Title : Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.

Pub. Date : 2009 Jun

PMID : 19002384






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Vandetanib (ZACTIMA) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. vandetanib epidermal growth factor Homo sapiens